TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10367219
Drug: Aspirin (asa)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (asa) 160 mg/die plus low-intensity oral anticoagulation (target INR: 1.5-2.5)
Study: 10367219
Drug: Picotamide (pico)
Normalized name: picotamide
DrugBank: Picotamide (DB13327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (pico) 300 mg/tid plus low-intensity oral anticoagulation
Study: 2188797
Drug: Intramuscular flupenthixol
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular flupenthixol decanoate (5 to 10 mg/fortnight)
Study: 2188797
Drug: Oral amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amitriptyline (75 to 150 mg/day)
Study: 24261310
Drug: Preventive laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive laser therapy (red or infrared) for 5 days starting on the 1st day of infusion
Study: 24261310
Drug: Therapeutic laser
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic laser therapy (red or infrared) only if mucositis developed
Study: 17298645
Drug: Minnesota day
Normalized name: influenza A virus A/Minnesota/41/2019 (H3N2) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minnesota day clinic treatment
Study: 17298645
Drug: Public out‐patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Public out‐patient alcohol clinic treatment
Study: 10633536
Drug: Lying posture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lying posture (L) for 20 min
Study: 3893128
Drug: 135 mEq/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mEq/l sodium dialysate
Study: 3893128
Drug: 143 mEq/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 143 mEq/l sodium dialysate
Study: 26324250
Drug: Nicotine concentration
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine concentration of 8 mg/mL
Study: 22464410
Drug: OC (2
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OC (2 mg chlormadinone acetate/30 mcg ethinylestradiol)
Study: 11939435
Drug: Isoprenaline (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (both doses)
Study: 20716712
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (2 g/day)
Study: 15807876
Drug: GH 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 0.1 IU/kg/day [0.033 mg/kg/day]
Study: 8874372
Drug: Glipizide (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide (maximum daily dosage)
Study: 8874372
Drug: Glyburide (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (maximum daily dosage)
Study: 8874372
Drug: First-generation sulfonylurea
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation sulfonylurea agents
Study: 1172599
Drug: beta‐acetyldigoxin in
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐acetyldigoxin in alcoholic solution
Study: 4850376
Drug: digoxin solution
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: digoxin solution
Study: 12436805
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) - ten sessions
Study: 12436805
Drug: Fluoxetine -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine - 20 mg daily
Study: 12436805
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (CBT plus fluoxetine)
Study: 10359466
Drug: Psychodynamic-interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic-interpersonal psychotherapy (8 weekly sessions)
Study: 8537197
Drug: 0.2 mg/ml
Normalized name: iodine 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/ml of Mitomycin C (MMC)
Study: 31148988
Drug: Fenugreek 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek 2 g/day
Study: 31148988
Drug: Glibenclamide 5
Normalized name: glibenclamide 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 5 mg once daily
Study: 28277854
Drug: Mepolizumab 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 75 mg intravenous (IV)
Study: 29949045
Drug: Mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 100 mg subcutaneous (SC)
Study: 26621118
Drug: XM17 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: XM17 (300 IU subcutaneous)
Study: 15457551
Drug: IFN-alpha2b +
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2b + ribavirin (treatment group = TG)
Study: 15457551
Drug: Old treatment
Normalized name: GLYCERIN 0.01 g in 1 mL TOPICAL LIQUID [BURZANGMURY GOLD TREATMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old treatment control group (OTCG) with IFN-alpha2b
Study: 29565472
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) with no treatment
Study: 11466162
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb) administered for 30 days
Study: 7697239
Drug: TOPA (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOPA (10% lidocaine spray and 0.25% bupivocaine gargle)
Study: 2689014
Drug: Terbinafine 125
Normalized name: terbinafine 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 125 mg b.i.d.
Study: 2689014
Drug: Griseofulvin 250
Normalized name: griseofulvin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 250 mg (microsize) b.i.d.
Study: 22892141
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behaviour therapy (CBT) after psycho-education materials
Study: 21493672
Drug: Oxandrolone (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (0.05 mg/kg/day, maximum 2.5 mg/day)
Study: 19621690
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g AzOAB: Azithromycin 500 mg twice daily for 3 days and Omeprazole 20 mg, Amoxicillin 1 g, Bismuth 240 mg all twice daily for 1 week
Study: 8279244
Drug: Alfentanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 20 micrograms.kg‐1 + lidocaine 1 mg.kg‐1
Study: 26147383
Drug: B-vitamin supplementation
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin supplementation (500 μg vitamin B12 and 400 μg folic acid)
Study: 19912283
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem (DTZ) ointment (2%; n = 16)
Study: 2909831
Drug: Aspartame (APM)
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (APM) at 10 mg APM/kg body weight per serving, ingested in three successive 12-oz servings at 2-hour intervals (study 1)
Study: 2645561
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg (q.i.d.)
Study: 2645561
Drug: Nefopam 60
Normalized name: nefopam 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 60 mg (q.i.d.)
Study: 2645561
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 640 mg + codeine 40 mg (q.i.d.)
Study: 31325020
Drug: Positional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positional therapy (PT)
Study: 23039931
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS treatment (n = 13)
Study: 23039931
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS treatment (n = 12)
Study: 28863074
Drug: Pro-CHO (CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro-CHO (CHO (15 g) + whey protein (10 g))
Study: 18719788
Drug: Dexmedetomidine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine group (n=13): infusion of 1 microg/kg over 10 minutes and maintenance dose of 0.5 microg/kg/h as an adjuvant to inhaled isoflurane anesthesia
Study: 18719788
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=13): normal saline infusion at a similar rate and volume of the dexmedetomidine infusion
Study: 17027362
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg mifepristone (group I)
Study: 20684146
Drug: 15% azelaic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% azelaic acid gel
Study: 11078311
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (900 calories, 50 g of fat)
Study: 11078311
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (900 calories, 4 g of fat)
Study: 30420421
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor or ARB monotherapy or combination therapy
Study: 27593617
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (140 ml daily, containing approximately 10 mmol of nitrate)
Study: 22081005
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg/day)
Study: 22193531
Drug: Fluoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10 mg/day to 80 mg/day over 12 weeks)
Study: 18197096
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg/dose
Study: 8137520
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg, subcutaneous injection)
Study: 2573377
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tertatolol (T)
Study: 2573377
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg atenolol (A)
Study: 1053694
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (chemotherapy and irradiation)
Study: 22428494
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg of ketamine (Group K2)
Study: 17143189
Drug: mibefradil 100
Normalized name: mibefradil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mibefradil 100 mg daily
Study: 17143189
Drug: amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine 10 mg daily
Study: 15334195
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) 2 mg/day, po with CsA (8-10 mg/kg/day, po) and prednisone (0.5 mg/day, po)
Study: 2506754
Drug: Rilmenidine 1
Normalized name: rilmenidine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine 1 mg and 2 mg
Study: 1098875
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg on the first day followed by 100 mg daily for a total of 7 days)
Study: 1098875
Drug: Ampicillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (250 mg 4 times daily for 7 days)
Study: 17722826
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with the same methods as the treatment group but without acupuncture at the acute stage.
Study: 7855937
Drug: Conventional digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional digital rectal examination (DRE)
Study: 10431942
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of caffeine
Study: 3602266
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 mg)
Study: 770365
Drug: nialamide +
Normalized name: nialamide
DrugBank: Nialamide (DB04820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nialamide + l-5-HTP
Study: 26541963
Drug: Mentor Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentor Support by mentors with a visual impairment in combination with care-as-usual
Study: 26541963
Drug: Mentor Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentor Support by mentors without visual impairments in combination with care-as-usual
Study: 9152683
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d beta-carotene and placebo for alpha-tocopherol
Study: 25187667
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg/day) from day 5 to day 7
Study: 22208477
Drug: Liu Wei
Normalized name: Bai Liu Bark
DrugBank: Salix alba bark (DB14274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liu Wei Di Huang Wan (LDW) 4.8 g (12 pills, 0.2 g/pill, twice daily) for 14 days
Study: 20660002
Drug: Radioiodine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine treatment
Study: 26637849
Drug: Oral progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral progestin (10 mg medroxyprogesterone acetate (MPA) taken continuously)
Study: 19178095
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (InT) performed within 24 hours
Study: 19178095
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CoT) with one treatment session a week for 4 weeks
Study: 453892
Drug: SEUV TG
Normalized name: TG-1042
DrugBank: TG-1042 (DB18435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEUV TG (suberythemogenic ultraviolet phototherapy with tar gel)
Study: 453892
Drug: Modified Goeckerman
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Goeckerman (erythemogenic tar gel phototherapy regimen)
Study: 453892
Drug: Tar gel
Normalized name: Betatar Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tar gel alone
Study: 453892
Drug: SEUV irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SEUV irradiation following application of gel vehicle
Study: 24983350
Drug: MVG 1.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVG 1.3% once daily for 3 days
Study: 24983350
Drug: MVG 1.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVG 1.3% once daily for 5 days
Study: 24983350
Drug: MVG 0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVG 0.75% once daily for 5 days
Study: 12928870
Drug: Imidacloprid 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidacloprid 10% w/v / Permethrin 50% w/v combination
Study: 10945514
Drug: Combination hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination hydrocodone 7.5 mg and ibuprofen 200 mg (2-tablet dose)
Study: 8495454
Drug: Domperidone 30
Normalized name: domperidone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 30 mg plus paracetamol 1 g
Study: 8495454
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g alone
Study: 30290667
Drug: Desflurane inhalation
Normalized name: Desflurane Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desflurane inhalation anesthesia
Study: 27758944
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg once daily for 90 days
Study: 27758944
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment in patients receiving tissue‐type plasminogen activator
Study: 23494629
Drug: 300‐U onabotulinumtoxinA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300‐U onabotulinumtoxinA injections
Study: 12928982
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg daily) after a montelukast-free period of one day
Study: 12928982
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg daily) after a montelukast-free period of three days
Study: 10026401
Drug: Kerasal 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kerasal 5% ointment
Study: 9620898
Drug: HR3 (rifampin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR3 (rifampin plus isoniazid, 3 times weekly)
Study: 9620898
Drug: HRp1 (rifapentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRp1 (rifapentine plus isoniazid, once weekly)
Study: 22992296
Drug: Combination NRT
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination NRT for 2 weeks
Study: 22992296
Drug: 2-week combination
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week combination NRT
Study: 22992296
Drug: 6-week combination
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week combination NRT
Study: 21256048
Drug: Tadalafil 40
Normalized name: tadalafil 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 40 mg
Study: 3569063
Drug: Ismo 20
Normalized name: Ismo 20mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ismo 20 (40 mg IS-5-N daily)
Study: 3569063
Drug: Corangin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corangin 20 (40 mg IS-5-N daily)
Study: 3569063
Drug: Corangin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corangin 40 (40 mg IS-5-N once a day)
Study: 3569063
Drug: Corangin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corangin 60 (60 mg IS-5-N once a day)
Study: 3569063
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release preparations (Corangin 40 and Corangin 60)
Study: 24886681
Drug: Granulocyte colony‐stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony‐stimulating factor (G‐CSF) for 5 days followed by autologous MSCs peripheral‐vein infusion
Study: 22225697
Drug: GPM +
Normalized name: PHENYLADE GPM ULTRA POWDER PACKET,33.4GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPM + DBT‐M treatment
Study: 20041478
Drug: Psychosocial interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychosocial interventions targeting medication adherence as a secondary outcome
Study: 16364056
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole orally for 2 days b.i.d.
Study: 10447055
Drug: Liquid cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid cooling (L)
Study: 28696373
Drug: Weekly upper
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly upper limb rehabilitation for 24 weeks
Study: 21724070
Drug: 8% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% hydrogen peroxide bleaching agent after orthodontic treatment (group B)
Study: 16739368
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole MUPS
Study: 31096515
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg esomeprazole
Study: 8687090
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by thymosin alpha1 + low-dose IFNalpha
Study: 8687090
Drug: Chemotherapy (ifosfamide)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (ifosfamide)
Study: 25715364
Drug: HIFU combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFU combined with chemotherapy (group B)
Study: 1532198
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (group A)
Study: 19041284
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of sustained-release isradipine
Study: 15051743
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (500 mg bid)
Study: 15888797
Drug: PEG‐IFN‐alpha‐2b (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐alpha‐2b (1.5 mug/kg) once weekly plus daily ribavirin (1000‐1200 mg) for 48 weeks
Study: 7638969
Drug: Isosorbide-5-mononitrate (IS-5-MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5-MN) 60 mg once daily
Study: 19994687
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Valaciclovir Hydrochlordide, Indomethacin, Vitamin B1 and Vitamin B12
Study: 16962390
Drug: Tropisetron preparation
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron preparation 1
Study: 7894213
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nifedipine GITS administered at 1000 hours
Study: 7894213
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nifedipine GITS administered at 2200 hours
Study: 26677212
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1.0 g/d)
Study: 12354713
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide with oxygen
Study: 766252
Drug: Intrathoracic BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathoracic BCG (single dose)
Study: 30980514
Drug: golimumab 2
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: golimumab 2 mg/kg at weeks 0, 4, and every 8 weeks thereafter
Study: 30980514
Drug: golimumab 2
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: golimumab 2 mg/kg
Study: 19639067
Drug: Two-implant group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant group
Study: 19639067
Drug: Single-implant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-implant group
Study: 3470961
Drug: PGE1 treatment
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 treatment group
Study: 3286673
Drug: Pulsatile insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile insulin delivery (5.2 mU kg‐1 min‐1, 2/11 min on/off)